Abstract:Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45 + cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.

Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors

Metabolism: an important player in glioma survival and development

Lipid metabolic rewiring in glioma‑associated microglia/macrophages (Review)

Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma

Regulation of tumor immunity by metabolism of glioma cells and immune cells in tumor microenvironment

Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets

Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma

Exploring potential therapeutic targets for glioma based on non-targeted metabolic analysis

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment

Metabolic regulation on the immune environment of glioma through gut microbiota

Targeted Arginine Metabolism Therapy: A Dilemma in Glioma Treatment

The Role of Tumor Metabolic Reprogramming in Tumor Immunity

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Role of Glycolytic and Glutamine Metabolism Reprogramming on the Proliferation, Invasion, and Apoptosis Resistance through Modulation of Signaling Pathways in Glioblastoma

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond

Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment

Metabolic dysregulation of tricarboxylic acid cycle and oxidative phosphorylation in glioblastoma

Autophagy Mediates Glucose Starvation-Induced Glioblastoma Cell Quiescence and Chemoresistance Through Coordinating Cell Metabolism, Cell Cycle, and Survival

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma